I-Mab Completes Enrollment in Phase 1b Study for Givastomig in Gastric Cancer

I-MAB ( (IMAB) ) has provided an announcement.

On August 11, 2025, I-Mab announced the completion of enrollment in its Phase 1b dose expansion study for givastomig, a bispecific antibody, in combination with immunochemotherapy for first-line gastric cancer treatment. The study, which enrolled 40 patients in the U.S., aims to evaluate the safety and efficacy of givastomig, with topline results expected in Q1 2026. The accelerated enrollment and positive preliminary data presented at ESMO GI highlight the potential of givastomig as a new treatment option, underscoring the unmet need in gastric cancer therapy and the growing interest in Claudin 18.2-directed therapies.

The most recent analyst rating on (IMAB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on I-MAB stock, see the IMAB Stock Forecast page.

Spark’s Take on IMAB Stock

According to Spark, TipRanks’ AI Analyst, IMAB is a Neutral.

The overall stock score of 45 reflects I-MAB’s substantial financial challenges, particularly in terms of profitability and cash flow generation, which heavily impact its financial performance. Despite a modest technical uptrend, valuation metrics point to significant risks, with ongoing losses and a negative P/E ratio limiting its appeal. The absence of recent earnings call data or notable corporate events further solidifies the overall cautious outlook.

To see Spark’s full report on IMAB stock, click here.

More about I-MAB

I-Mab is a U.S.-based global biotech company focused on developing precision immuno-oncology agents for cancer treatment. The company’s leading product is givastomig, a bispecific antibody targeting Claudin 18.2-positive gastric cancers, designed to activate T cells in the tumor microenvironment.

Average Trading Volume: 1,589,583

Technical Sentiment Signal: Buy

Current Market Cap: $269.2M

See more insights into IMAB stock on TipRanks’ Stock Analysis page.